◎记者 赵明超 随着A股震荡上行，市场热度持续升温。定增市场上，公募基金的参与热情也显著提升，今年以来总认 购金额已突破300亿元，超过去年全年水平。从参与定增的基金看，不乏朱少醒、葛兰等百亿级基金经 理所管理的基金产品。 Choice数据显示，以增发公告日为基准，截至10月9日，今年以来，共有34家基金公司参与了定增并获 配股份，认购金额合计达到301.21亿元。2024年全年，共有22家基金公司参与定增并获配股份，认购总 金额为296.51亿元。 从各家基金公司的认购总金额来看，今年以来，诺德基金、财通基金认购总金额均超过80亿元，易方达 基金、广发基金、兴证全球基金等认购的总金额均超过12亿元。 在部分热门标的上，公募基金成为定增股份的认购主力。以热门股寒武纪为例，根据该公司发布的定增 公告，此次募集资金总额为39.85亿元，在最终确定的13家发行对象中，有8家为公募基金公司，其获配 总金额为25.25亿元，占募集资金总额的六成以上。 从基金公司披露的信息看，多位知名基金经理管理的产品参与了上市公司定增，重点参与了高端制造、 医药等行业公司。 具体来看，近日，中欧基金发布关于旗下部分基金投资创新药龙头公 ...

Core Viewpoint - The recent announcement by China Europe Fund regarding the appointment of Zhao Lei as a co-manager for the China Europe Medical Health Mixed Fund has raised concerns among investors, particularly in light of the fund's significant losses over the past three years, leading to speculation about the future of the fund and its management [1][5][19] Fund Management Changes - The China Europe Medical Health Mixed Fund, with a total scale of 311.79 billion yuan, has appointed Zhao Lei to co-manage alongside the well-known manager Ge Lan [1][2] - Zhao Lei has 8 years of experience in the securities industry, primarily focused on medical research, but lacks independent management experience of large-scale funds [3][14] Performance Metrics - The fund has experienced a net value decline of 39.40% over the past three years, significantly underperforming its peers, which averaged a decline of 15.85%, and the CSI 300 index, which fell by 10.76% [8][10] - The fund's performance has deteriorated sharply, with a peak return of 90.57% in 2021, followed by three consecutive years of losses that have diluted long-term returns [8][10] Investor Sentiment - Investor sentiment has turned negative, with many expressing concerns about the management changes and the fund's performance, leading to speculation about potential withdrawals from the fund [5][19] - The shift in management strategy, including the appointment of a co-manager, has raised questions about the future direction of the fund and the distribution of decision-making power between Ge Lan and Zhao Lei [14][19] Industry Context - The medical sector is currently facing challenges due to policy adjustments and overcapacity, impacting the performance of key stocks previously favored by Ge Lan [16][17] - The ongoing struggles in the medical sector may complicate Zhao Lei's ability to balance high-research investment stocks with low-valuation consumer medical stocks, potentially affecting the fund's future performance [18][19]

Group 1: Fundraising and Investment Trends - Several new pharmaceutical-themed funds have shortened their fundraising periods due to rapid stock price increases in innovative drugs, with some funds ending their fundraising early, such as the Dongfang Alpha Health Industry Fund, which closed on June 10 instead of June 13 [1] - The Ping An Hong Kong Stock Connect Medical Innovation Selected Fund also announced an early closure of its fundraising, originally set to end on June 25 [1] Group 2: Bond Fund Restrictions - Over ten public fund institutions, including China Merchants Fund and Dongfang Fund, announced restrictions on large subscriptions for certain bond funds, with varying limits on subscription amounts [2] - For instance, the Dongfang Zhenyu Bond Fund has a subscription limit of 10,000 yuan, while several funds under ICBC Credit Suisse have a limit of 10 million yuan for institutional investors starting June 11 [2] Group 3: Fund Performance Recovery - More than 60% of actively managed equity funds have recovered from previous performance declines, driven by sectors such as innovative drugs, new consumption, gold, and AI, with some funds seeing net value rebounds of over 30% in the past two months [4] - Funds like Changcheng Pharmaceutical Industry Selected A and Zhonghang Preferred Navigation A have shown significant performance improvements, with year-to-date returns exceeding 70% [4] Group 4: New Fund Share Classes - Public funds have been increasingly announcing the addition of new "niche" share classes, such as E shares for Ping An CSI A50 ETF and D shares for Jiahe Panheng Bond Fund, indicating a trend towards diversifying fund offerings [5] - The increase in "niche" share classes, particularly for fixed-income and index products, contrasts with the more common addition of B and C shares in the past [5] Group 5: Market Activity and ETF Performance - On June 11, the market experienced a rebound, with the Shanghai Composite Index rising by 0.52% and the Shenzhen Component Index by 0.83%, while the total trading volume was 1.26 trillion yuan, down by 159.9 billion yuan from the previous trading day [8] - Sectors such as rare metals and gaming saw significant gains, while biopharmaceuticals and communication services faced declines [8][9]

Group 1 - Multiple new funds targeting the pharmaceutical sector have shortened their fundraising periods, with the Oriental Alpha Health Industry Fund ceasing investor subscriptions after just 4 trading days starting June 10 [1] - Over 10 public fund institutions, including China Merchants Fund and Oriental Fund, announced restrictions on large subscriptions for certain bond funds on June 10, indicating a trend of "limited purchases" in the bond fund sector [2] - Guoxin Guozheng Fund issued a warning about fraudulent activities, where criminals impersonate the company and its employees to deceive investors into joining chat groups and downloading illegal applications [3] Group 2 - Fund manager Ge Lan has increased her stake in Mai Pu Medical, with the latest report showing her fund holding 2.4396 million shares as of May 21, marking her first appearance in the top ten circulating shareholders [4] - The ETF market experienced a rebound, with the Shanghai Composite Index rising by 0.52%, the Shenzhen Component Index by 0.83%, and the ChiNext Index by 1.21%, while the total trading volume decreased by 159.9 billion yuan compared to the previous trading day [5] - The rare earth sector is expected to continue optimizing its supply-demand dynamics, driven by growth in demand from electric vehicles, wind power, and robotics, suggesting potential investment opportunities in rare earth ETFs [8] Group 3 - A new fund, CITIC Securities CSI A500 Index Enhanced Fund, is set to launch, managed by Wang Peng, with a performance benchmark of 95% of the CSI A500 Index return plus 5% of the after-tax bank demand deposit rate [9]

Group 1 - Fund managers are actively seeking new investment opportunities through a combination of portfolio adjustments and research activities in the current market environment [1] - Notable changes in shareholder structures of several A-share listed companies indicate clear investment trends from well-known fund managers [3] - The latest data shows significant increases in holdings for certain funds, such as the Guangfa High-end Manufacturing Fund, which increased its stake substantially compared to the previous quarter [3] Group 2 - Institutional research activities are intensifying, with BoShi Fund leading with 945 research engagements, followed by HuaXia Fund with 867 [4] - Prominent fund managers are frequently participating in company research activities, focusing on key topics such as capital expenditure planning and technology iteration [4] - YiHeDa has gained the highest attention in research activities in June, with several well-known institutions participating in discussions on various topics including drug development and international cooperation [4]

Group 1 - Yu Haichun has been appointed as the new chairman of Huafu Fund, succeeding Zhao Wanli who left due to work adjustments. Yu has 34 years of experience in the securities industry [1] - Morgan Fund announced an investment of no less than 54 million RMB in its newly launched equity public fund, demonstrating confidence in the long-term potential of the Chinese capital market [2] - Fangzheng Fubon Fund will invest 5 million RMB of its own funds in the Fangzheng Fubon CSI All Share Free Cash Flow ETF, also committing to hold for at least one year [2] Group 2 - As of March 2025, the total net asset value of public funds in China reached 32.22 trillion RMB, with 163 fund management institutions [3] - In March, various types of funds saw net subscriptions, with stock funds reaching 3.4 trillion shares, a 1.29% increase from the previous month [3] - QDII funds experienced the highest subscription activity in March, with a 3.57% increase in shares, totaling 562.68 billion shares [3] Group 3 - Over 70% of actively managed equity funds have increased their holdings in Hong Kong stocks, with a total market value increase of 98.25 billion RMB in the first quarter, reaching a three-year peak [4] - The average allocation to Hong Kong stocks among these funds rose to 25.79%, the highest level in five years [4] Group 4 - Wanminyuan has slightly reduced its holdings in Dongfang Biology, with the number of shares held decreasing from 4.71 million to 4.22 million in the first quarter of 2025 [5] - The fund managed by Wanminyuan is identified as the Rongtong Health Industry Fund [5] Group 5 - The Yi Nuo Si company has seen an increase in holdings by the Zhongou Medical Health Mixed Fund managed by Ge Lan, which now holds 403,100 shares, up from 99,500 shares at the end of the previous year [7] - Yi Nuo Si specializes in providing comprehensive R&D services for high-quality innovative drugs in the biopharmaceutical sector [7] Group 6 - On April 30, the market showed mixed performance, with the Shanghai Composite Index down 0.23% and the Shenzhen Component Index up 0.51% [8] - The total trading volume in the Shanghai and Shenzhen markets reached 1.17 trillion RMB, an increase of 147.2 billion RMB from the previous trading day [8] - AI-related ETFs in the Sci-Tech Innovation Board saw significant gains, while bank stocks collectively adjusted downwards [8]

Group 1: Fund News - Yu Haichun has been appointed as the new chairman of Huafu Fund, succeeding Zhao Wanli who left due to work adjustments. Yu has 34 years of experience in the securities industry [1] - Morgan Fund plans to repurchase at least 54 million RMB of its newly launched equity public fund, committing to hold the investment for at least one year [1] - The total scale of public funds in China has remained above 32 trillion RMB for two consecutive months, with a net asset value of 32.22 trillion RMB as of March 31, 2025 [1] Group 2: Fund Manager Activities - Wan Minyuan's Rongtong Health Industry Fund has slightly reduced its holdings in Dongfang Biology, decreasing its share count by 489,000 shares compared to the end of last year [2] - Ge Lan's Zhongou Medical Health Mixed Fund has increased its position in Yinuosi, holding 403,100 shares, up from 99,500 shares at the end of last year, representing an increase of 303,600 shares [2] Group 3: ETF Market Overview - The market experienced fluctuations, with the Shanghai Composite Index down 0.23%, while the Shenzhen Component Index and the ChiNext Index rose by 0.51% and 0.83%, respectively. The total trading volume in both markets reached 1.17 trillion RMB, an increase of 147.2 billion RMB from the previous trading day [3] - AI-related ETFs on the Sci-Tech Innovation Board saw strong performance, with the highest increase reaching 4.30% [4] - Bank ETFs collectively declined, with the highest drop recorded at 2.19% [5] Group 4: ETF Investment Opportunities - Analysts suggest that despite increased market risk appetite, external disturbances remain. Domestic policies are expected to maintain stability, with potential for further reserve requirement ratio cuts and interest rate reductions, supporting bank valuations and credit conditions [6] Group 5: New Fund Launches - E Fund has launched the E Fund CSI Digital Economy Theme ETF, managed by Pang Yaping, which aims to track the performance of the CSI Digital Economy Theme Index [7] - Tianhong has introduced the Tianhong Guozheng Aerospace Industry ETF, managed by Sha Chuan, with a performance benchmark based on the Guozheng Aerospace Industry Index [10]

Group 1 - Jianxin Fund plans to invest at least 180 million yuan in its equity public products, having already invested 173 million yuan from Q4 2024 to Q1 2025 [1] - Multiple Hong Kong Stock Connect ETFs have issued warnings about premium risks due to high trading activity during the market closure, with some ETFs experiencing daily turnover rates exceeding 900% [1] - QDII funds have significantly reduced their holdings in US stocks, reallocating to A-shares and Hong Kong stocks [1] Group 2 - Fund manager Ge Lan has reduced her stake in Xinlitai by 2.1673 million shares, as reported in the company's Q1 2025 report [2] - Fund manager Fu Pengbo has slightly increased his position in Furuide by 120,000 shares, according to the latest Q1 2025 report [2] - Fund manager Xiao Nan has increased the allocation to liquor stocks, viewing it as a high-yield bond with domestic demand upside [3] Group 3 - The market showed mixed performance with the Shanghai Composite Index up 0.25% and the Shenzhen Component down 0.36%, with a total trading volume of 1.09 trillion yuan [4] - Hong Kong innovative drug-related ETFs saw strong performance, with some rising by as much as 5.77% [4][5] - A report indicates that the pharmaceutical sector may attract market funds due to previous declines, with investment opportunities focusing on innovative and generic drugs, as well as medical devices and services [7] Group 4 - A new fund, the China Securities Index Free Cash Flow ETF, is set to launch, managed by Xu Rongman, with a performance benchmark based on the China Securities Index Free Cash Flow Index [8]

Group 1 - As of the end of February 2025, the total net asset value of public funds in China reached 32.23 trillion yuan, with a month-on-month increase of 294.21 billion yuan, representing a growth of 0.92% [1] - The number of public fund management institutions in China stands at 163, including 148 fund management companies and 15 asset management institutions with public qualifications [1] - The stock fund size reached a historical high of 4.48 trillion yuan, with a monthly increase of 909.14 billion yuan, reflecting a growth rate of 2.07% [1] Group 2 - A total of 14 new funds related to the Science and Technology Innovation Board Index have been approved, including 11 enhanced index funds and 3 index funds [2] - The Science and Technology Innovation Board Index covers over 40 secondary industries, with significant weight in sectors such as semiconductors, medical devices, and software [2] Group 3 - The first batch of annual reports for the CSI A500 ETF was released, showing a significant presence of insurance institutions among the top ten shareholders [3] - Major insurance companies collectively held over 30% of the shares in the Invesco Great Wall CSI A500 ETF, indicating strong institutional interest [3] Group 4 - The annual report of Haoyuan Pharmaceutical revealed that the fund managed by Guo Lan has acquired 7.0021 million shares, marking its first appearance among the top ten circulating shareholders [4] - The annual report of China National Airlines indicated that the fund managed by Xie Zhiyu has acquired 46.7308 million shares, also marking its first appearance among the top ten circulating shareholders [5] - The annual report of Shanghai Yanpu showed that the fund managed by Zhu Shaoxing has acquired 1.2227 million shares, marking its first appearance among the top ten circulating shareholders [6] - The annual report of Fanwei Network indicated that the fund managed by Zhai Xiangdong has acquired 4.5 million shares, marking its first appearance among the top ten circulating shareholders [7] Group 5 - On March 28, the market experienced fluctuations, with the Shanghai Composite Index falling by 0.67% and the Shenzhen Component Index by 0.57% [8] - The New Economy ETF led the market with a gain of 6.66%, reaching a near three-year high in secondary market prices [8] - Gold stocks surged against the market trend, with West Mining hitting the daily limit, and related ETFs performing strongly [9]